Moderna (NASDAQ:MRNA) Hits New 12-Month Low – What’s Next?

Moderna, Inc. (NASDAQ:MRNA) shares hit a new 52-week low on Wednesday . The company traded as low as $52.77 and last traded at $53.04, with a volume of 805110 shares. The stock had previously closed at $53.40.

Wall Street Analyst Weigh In

A number of research firms have commented on MRNA. The Goldman Sachs Group reduced their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Bank of America decreased their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research report on Friday, September 13th. Finally, William Blair reissued a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus price target of $94.65.

Moderna Price Performance

The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company has a fifty day moving average of $68.35 and a two-hundred day moving average of $103.20.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same quarter last year, the firm posted ($3.62) EPS. The company’s revenue was down 29.9% on a year-over-year basis. Equities analysts expect that Moderna, Inc. will post -9.94 earnings per share for the current year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total value of $1,799,400.00. Following the transaction, the director now owns 2,224,015 shares in the company, valued at $266,792,839.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,184 shares of company stock valued at $2,037,931 in the last ninety days. Company insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

A number of institutional investors have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna during the 2nd quarter worth about $26,000. Cedar Wealth Management LLC raised its holdings in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares in the last quarter. Westside Investment Management Inc. acquired a new stake in Moderna in the 1st quarter valued at $32,000. Family Firm Inc. bought a new stake in Moderna in the second quarter valued at $33,000. Finally, Bank & Trust Co acquired a new position in Moderna during the second quarter worth $36,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.